Aesthetics
November 19, 2021
Pre-clinical Data on KB303 Presented at ASDS 2021
Summary: Jeune Aesthetics, Inc., a subsidiary of Krystal Biotech, Inc., presented new pre-clinical data on KB303, an investigational, redosable gene therapy in development for the treatment of age- or environment-related loss in cutaneous elasticity, at the American Society for Dermatologic Surgery (ASDS) 2021 Virtual Meeting held November 19-21, 2021.
- Read More 1.4 MB
May 3, 2021
New Safety Data from the GEM-1 Phase 1/2 Study of B-VEC and the Phase 1 Study of KB301 Presented at SID 2021
Summary: During the Society for Investigative Dermatology (SID) Annual Meeting held virtually May 3-8, 2021, we presented new safety results from our GEM-1 Phase 1/2 study of beremagene geperpavec (B-VEC), an investigational, topical, redosable gene therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB) and from the Phase 1 study of KB301, an investigational, redosable gene therapy, for the treatment of aesthetic skin conditions.
- Presentation 371.6 KB
- Presentation 533.9 KB
October 9, 2020
Preclinical Data for KB301 Presented at ASDS 2020
Summary: New in vitro and in vivo data on KB301, an investigational, redosable gene therapy in development for the treatment of aesthetic skin conditions, was presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting held October 9-11, 2020.
- Read More 1.7 MB